Back to the future: proceedings from the 2010 NF Conference

Area of Science:

• Genetics and Molecular Biology
• Oncology
• Neurology

Background:

• Neurofibromatoses (NF) comprise NF1, NF2, and schwannomatosis, rare genetic disorders caused by tumor suppressor gene mutations.
• These conditions affect over 2 million people globally, with NF1 leading to diverse symptoms including tumors, learning disabilities, and increased cancer risk.
• NF can result in severe outcomes such as blindness, deafness, significant morbidity, and mortality.

Framework:

• The 2010 Children's Tumor Foundation conference convened over 300 NF researchers and clinicians.
• This paper synthesizes key findings and advancements presented at the conference, offering a 2010 snapshot of the NF research landscape.
• Focus areas included understanding molecular signaling deficits, preclinical drug screening, and clinical trial development.

Implementation:

• Research is advancing understanding of the molecular signaling deficits underlying NF manifestations.
• Preclinical drug screening initiatives are growing, paving the way for potential therapeutic interventions.
• Multiple clinical trials are emerging, representing a significant step towards effective treatments for NF.

Implications:

• Despite no current cures, recent research strides offer hope for effective treatments for neurofibromatoses.
• Continued collaboration and knowledge sharing, exemplified by the annual NF Conference, are crucial for accelerating progress.
• The identified research advancements suggest a promising future for individuals affected by NF1, NF2, and schwannomatosis.